Arecor Therapeutics PLC (AIM:AREC) said its Tetris Pharma subsidiary has signed a service agreement with Nasdaq-listed Syneos Health to help build a commercial platform across Europe.
Syneos will provide commercial support and build healthcare sector awareness of Tetris’ flagship diabetes product Ogluo as it rolls out from its UK base.
In a statement, Shafiq Choudhary, Tetris’ MD, said: "Following the recent launch of Ogluo (glucagon prefilled autoinjector pen) in Germany, we are focused on continuing its accelerated roll-out across Europe.
“Syneos Health was one of several potential partners that were evaluated during the process of partnering with an organisation that would provide a multitude of commercial options to help establish the product across Europe.
“Partnering with Syneos Health, a leader in clinical research, medical affairs, and commercialisation services for the pharmaceutical industry is key to building our reputation.”